Page last updated: 2024-11-05

protactinium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Protactinium (Pa) is a radioactive metallic element found in trace amounts in uranium ores. It is a silvery-white, highly dense, and chemically reactive metal. It is primarily produced as a byproduct of uranium processing. Protactinium exists in two major isotopes: Protactinium-231 (Pa-231) and Protactinium-234 (Pa-234). Protactinium is not found in nature in its elemental form but is present as a radioactive decay product of uranium. It is a member of the actinide series and is a highly radioactive element. Its isotopes have a variety of applications in nuclear physics, including: 1. Studying the nuclear structure and decay processes of heavy elements. 2. Developing new types of nuclear reactors. 3. Performing nuclear medicine research. However, its high radioactivity makes it a potential health hazard, and its handling requires special precautions. Due to its radioactive nature, it is primarily studied in controlled laboratory settings.'

Protactinium: A radioactive element of the actinide group of metals. It has the atomic symbol Pa, atomic number 91, and atomic weight 231. It decays by alpha-emission. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23945
CHEBI ID33386
MeSH IDM0017841

Synonyms (15)

Synonym
pa
protactinium atom
protactinio
CHEBI:33386
protactinium
protoactinium
brevium
7440-13-3
91pa
unii-0s6855v29m
0s6855v29m ,
protactinium [mi]
eka-tantalum
DTXSID50225387
Q1109
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
actinoid atom
f-block element atom
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (65)

TimeframeStudies, This Drug (%)All Drugs %
pre-199031 (47.69)18.7374
1990's7 (10.77)18.2507
2000's12 (18.46)29.6817
2010's13 (20.00)24.3611
2020's2 (3.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 63.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index63.05 (24.57)
Research Supply Index4.22 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index103.14 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (63.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.99%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other65 (97.01%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]